N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; methanesulfonic acid

• ChemBase ID: 72466
• Molecular Formular: C30H35N7O4S
• Molecular Mass: 589.7084
• Monoisotopic Mass: 589.24712364
• SMILES: c1(ccc(c(c1)Nc1nccc(n1)c1cccnc1)C)NC(=O)c1ccc(cc1)CN1CCN(CC1)C.OS(=O)(=O)C
• Canonical SMILES: CS(=O)(=O)O.CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C
• InChI: InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)
• InChIKey: YLMAHDNUQAMNNX-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; methanesulfonic acid
• IUPAC Traditional name: imatinib mesylate mesylate; imatinib; methanesulfonic acid; N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide; methanesulfonic acid
• Synonyms: Gleevec; Glivec; CGP-571; Imatinib Mesylate; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Methanesulfonate; CGP 57148B; Gleevac; Imatinib Mesilate; Imatinib Mesylate; STI 571; Gleevec (Imatinib Mesylate); 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)phenyl]benzamide methanesulfonic acid salt; Imatinib Mesylate

Database IDs

• CAS Number: 220127-57-1
• MDL Number: MFCD04307699
• PubChem SID: 162037391
• PubChem CID: 123596

CALCULATED PROPERTIES

• Acid pKa: 12.454878
• H Acceptors: 7
• H Donor: 2
• LogD (pH = 5.5): 1.6563946
• LogD (pH = 7.4): 3.4515045
• Log P: 4.377673
• Molar Refractivity: 148.9293 cm^3
• Polarizability: 57.103134 Å^3
• Polar Surface Area: 86.28 Å^2
• Rotatable Bonds: 7
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: DMSO; Methanol,
• Apperance: Off-White to Light Beige Solid
• Melting Point: 214-224°C

Safety Information

• Storage Condition: -20°C; -20°C Freezer

Pharmacology Properties

• Target: c-Kit; PDGFR
• Mechanism of Action: Tyrosine kinase inhibitor

Product Information

• Purity: 95+%
• Salt Data: Mesylate
• Application(s): Antineoplastic agent; Used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies

DETAILS

Selleck Chemicals - S1026

Research Area

• Description: Cancer

Biological Activity

• Description: Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
• Targets: v-Abl; PDGFR; c-Kit
• IC50: 600 nM; 100 nM ^[1]; 100 nM ^[2]
• In Vitro: In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. ^[1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. ^[2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. ^[3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. ^[4]
• In Vivo: Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. ^[5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. ^[6]
• Clinical Trials: Imatinib is currently being investigated in Phase III clinical trials in patients with Sarcoma.

Protocol

• Protocol: Kinase Assay ^[1]
• PDGF receptor kinase activity: PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl₂). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-^33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
• Protocol: Cell Assay ^[3]
• Cell Lines: BON-1 cells and NCI-H727 cells
• Concentrations: ~100 μM
• Incubation Time: 48 hours
• Methods: BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 ? a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.
• Protocol: Animal Study ^[5]
• Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
• Formulation: Imatinib is diluted in water.
• Doses: 70 or 100 mg/kg
• Administration: Administered via i.p.

References

• References: [1] Buchdunger E, et al. Proc Natl Acad Sci USA, 1995, 92(7), 2558–2562.
• References: [2] Heinrich MC, et al. Blood. 2000, 96(3), 925-932.
• References: [3] Yao JC, et al. Clin Cancer Res. 2007, 13(1), 234-240.
• References: [4] Zheng F, et al. Med Oncol, 2012, 29(3), 2127-2135.
• References: [5] Decaudin D, et al. Int J Cancer. 2005, 113(5), 849-856.
• References: [6] Ballinger ML, et al. J Cell Mol Med. 2010,14(6B), 1408-1418.

Toronto Research Chemicals - G407000

A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL).

REFERENCES

• Decaudin D, et al. Int J Cancer. 2005, 113(5), 849-856.
• Buchdunger E, et al. Proc Natl Acad Sci USA, 1995, 92(7), 2558–2562.
• Heinrich MC, et al. Blood. 2000, 96(3), 925-932.
• Yao JC, et al. Clin Cancer Res. 2007, 13(1), 234-240.
• Zheng F, et al. Med Oncol, 2012, 29(3), 2127-2135.
• Ballinger ML, et al. J Cell Mol Med. 2010,14(6B), 1408-1418.
• Schindler, T., et al.: Science, 289, 1938 (2000)
• Drucker, B.J., et al.: N. Engl. J. Med., 344, 1031 (2000)
• Eur. Pat., 1993, Ciba-Geigy, 564 409; CA, 120, 107056w, (synth, pharmacol)
• Buchdunger, E. et al., Cancer Res., 1996, 56, 100-104, (pharmacol)
• Deininger, M.W.N. et al., Blood, 1997, 90, 3691-3698, (pharmacol)
• Deininger, M.W. et al., Cancer Res., 2000, 60, 2049-2055, (pharmacol)
• O'Dwyer, M.E. et al., Curr. Opin. Oncol., 2000, 12, 594-597, (rev)
• Gianni, M. et al., Blood, 2001, 97, 3234-3243, (pharmacol)
• Lyseng-Williamson, K. et al., Drugs, 2001, 61, 1765-1774, (rev)
• Mughal, T.I. et al., Eur. J. Cancer, 2001, 37, 561-568, (rev)